Collection of Sputum and Labeling for Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03457415|
Recruitment Status : Recruiting
First Posted : March 7, 2018
Last Update Posted : March 15, 2021
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization.
The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.
|Condition or disease|
This study will be performed at multiple study centers to collect sputum samples from three cohorts including (1) healthy Participants, (2) individuals at high risk for lung cancer and (3) individuals who have been diagnosed with lung cancer. Participants in the high risk cohort will undergo low dose computed tomography (LDCT) scans to confirm they do not have lung cancer. LDCT scans will be evaluated by a radiologist at each site. Each subject's sputum specimen will be processed in accordance with individual experimental protocol at the laboratory of bioAffinity Technologies, Inc. (BA) located at the University of Texas at San Antonio 1604 main campus in San Antonio, Texas, or at the Research DX laboratory in Irvine, California.
Once a sample is obtained and delivered to the laboratory, the Assay methodology consists of chemical dissociation of sputum to produce a single cell suspension sample that is labeled with antibodies to identify various types of cell populations in the sample. Thereafter, sputum samples are stained with the cancer detection compound, CyPath® Lung. This compound has a unique fluorescent spectrum that can be analyzed by a flow cytometer. The flow cytometric analysis confirms that the sample is from the deep lung and identifies various cell populations based on characteristics such as cell size, granularity, and antigen expression. Cancer samples can be distinguished from non-cancer samples by the presence of highly fluorescent cells labeled by CyPath®. In this manner, CyPath® can identify lung cancer cells and other distinguishing cells that have been sloughed off in the lungs and coughed up in the sputum sample, including cancer cells.
Researchers who will be blinded as to the Participant's identity will perform the experiments that compare the characteristics of samples collected by the alternate sample collection methods and labeled by CyPath® Lung. In the latter phase of the study, the analytical results of sputum sample analysis requires that the researchers be blinded to the classification of the sputum sample and methods of collection.
Findings from the CyPath® Lung Assay will not be used in the diagnosis of Participants or subsequent treatment decisions.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer|
|Actual Study Start Date :||March 1, 2018|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
- Identification of Differential Characteristics [ Time Frame: 320 days ]The primary outcome measure is to identify differential characteristics (using flow cytometry for high-throughput screening of Assay labeled sputum samples) between samples taken from healthy Participants, Participants at high risk for lung cancer who are free of the disease, and Participants with confirmed lung cancer.
- Sputum Collection Methodology [ Time Frame: 320 days ]The secondary endpoint is evaluation of the suitability of sputum samples collected by the three different methods.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03457415
|Contact: Maria Zannes, JDfirstname.lastname@example.org|
|Contact: Xavier Reveles, MSemail@example.com|
|United States, Connecticut|
|Waterbury Pulmonary Associates LLC||Recruiting|
|Waterbury, Connecticut, United States, 06708|
|Contact: Michele Anderson, LPN 203-759-3656 firstname.lastname@example.org|
|Principal Investigator: David G. Hill, MD|
|United States, New Jersey|
|Summit Medical Group||Withdrawn|
|Berkeley Heights, New Jersey, United States, 07922|
|Atlantic Respiratory Institute||Recruiting|
|Summit, New Jersey, United States, 07901|
|Contact: Marissa Rienton-Lim, CCRC 908-934-0440 email@example.com|
|Principal Investigator: Robert Sussman, MD|
|United States, New Mexico|
|Radiology Associates of Albuquerque||Recruiting|
|Albuquerque, New Mexico, United States, 87109|
|Contact: Timothy P. Zannes, JD 505-506-0853 firstname.lastname@example.org|
|Principal Investigator: Kathleen Lopez, MD|
|United States, New York|
|Department of Medicine-Clinical Trials Office - Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Contact: Diana Chispe-Valerio, BS 212-241-9538 email@example.com|
|Principal Investigator: Louis R DePalo, MD|
|United States, Tennessee|
|Cookeville Regional Medical Center - Cancer Center||Terminated|
|Cookeville, Tennessee, United States, 38501|
|United States, Texas|
|South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital||Recruiting|
|San Antonio, Texas, United States, 78229|
|Contact: Alexander Aguilera 210-834-1344 firstname.lastname@example.org|
|Principal Investigator: Sheila Habib, MD|